Paul D. Rubin's most recent trade in BioAge Labs Inc. was a trade of 7,433 Common Stock done at an average price of $18.8 . Disclosure was reported to the exchange on Feb. 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| BioAge Labs Inc | Paul D. Rubin | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.75 per share. | 02 Feb 2026 | 7,433 | 0 | - | 18.8 | 139,369 | Common Stock |
| BioAge Labs Inc | Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.11 per share. | 02 Feb 2026 | 5,433 | 5,433 | - | 4.1 | 22,330 | Common Stock |
| BioAge Labs Inc | Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2026 | 5,433 | 10,870 | - | - | Stock Option (Right to Buy) | |
| BioAge Labs Inc | Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2026 | 2,000 | 5,383 | - | - | Stock Option (Right to Buy) | |
| BioAge Labs Inc | Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.57 per share. | 02 Feb 2026 | 2,000 | 7,433 | - | 6.6 | 13,140 | Common Stock |
| BioAge Labs Inc | Paul D. Rubin | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.85 per share. | 02 Jan 2026 | 7,433 | 0 | - | 12.8 | 95,490 | Common Stock |
| BioAge Labs Inc | Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.11 per share. | 02 Jan 2026 | 5,433 | 5,433 | - | 4.1 | 22,330 | Common Stock |
| BioAge Labs Inc | Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 5,433 | 16,303 | - | - | Stock Option (Right to Buy) | |
| BioAge Labs Inc | Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.57 per share. | 02 Jan 2026 | 2,000 | 7,433 | - | 6.6 | 13,140 | Common Stock |
| BioAge Labs Inc | Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 2,000 | 7,383 | - | - | Stock Option (Right to Buy) | |
| BioAge Labs Inc | Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2025 | 18,000 | 9,383 | - | - | Stock Option (Right to Buy) | |
| BioAge Labs Inc | Paul D. Rubin | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 09 Dec 2025 | 18,000 | 0 | - | 12 | 216,000 | Common Stock |
| BioAge Labs Inc | Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.57 per share. | 09 Dec 2025 | 18,000 | 18,000 | - | 6.6 | 118,260 | Common Stock |
| BioAge Labs Inc | Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2025 | 68,897 | 21,736 | - | - | Stock Option (Right to Buy) | |
| BioAge Labs Inc | Paul D. Rubin | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.19 per share. | 04 Dec 2025 | 68,897 | 0 | - | 10.2 | 701,909 | Common Stock |
| BioAge Labs Inc | Paul D. Rubin | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.11 per share. | 04 Dec 2025 | 68,897 | 68,897 | - | 4.1 | 283,167 | Common Stock |
| BioAge Labs Inc | Paul D. Rubin | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) |